Biocircuits Corp. is coming out of its self-imposed quiet period, which began more than a year ago when the company decided to redesign its immunodiagnostic testing system. That process is nearing completion, and the Sunnyvale, Calif., company anticipates submitting a 510(k) in mid-June for the system and initial two assays, T4 and T Uptake, for determining thyroid dysfunction. The 510(k) will trigger an $8.7 million funding round.

BIOC's retrenchment began in late 1993, when the company found a mechanical flaw in its disposable cartridge system, which is designed to enable low-cost immunodiagnostic testing in doctor's offices and other point-of-care sites.